Did Phillip Frost or his related entities trade OPKO Health (OPK) shares in the last 60 days?

The amendment reports that Gamma Trust, Frost Nevada and Phillip Frost have not effected any transactions in OPKO Health common stock during the 60 days before this filing. The ownership update results from a change in OPKO’s outstanding share count, not from recent share purchases or sales.

Phillip Frost (NASDAQ: OPK) reports 34.1% beneficial stake in OPKO

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

OPKO Health’s major shareholder Phillip Frost reports beneficial ownership of 255,429,406 shares of common stock, or about 34.1% of shares outstanding. This reflects holdings through Gamma Trust, Frost Nevada Investments Trust, a philanthropic foundation, stock options and restricted stock units.

The amendment is being filed solely because OPKO’s outstanding share count changed to 746,328,225 as of June 29, 2026. Frost and affiliated trusts report no transactions in OPKO common stock during the 60 days before this amendment.

Key Figures

Frost beneficial ownership: 255,429,406 shares Frost ownership percentage: 34.1% Shares outstanding: 746,328,225 shares +5 more

8 metrics

Frost beneficial ownership 255,429,406 shares Aggregate OPKO common shares beneficially owned by Phillip Frost

Frost ownership percentage 34.1% Percent of OPKO common stock based on 746,328,225 shares outstanding

Shares outstanding 746,328,225 shares OPKO common shares outstanding as of June 29, 2026

Gamma Trust holdings 216,706,448 shares OPKO common shares directly owned by Frost Gamma Investments Trust

Gamma Trust percentage 29.0% Share of OPKO’s outstanding common stock held by Gamma Trust

Frost Nevada holdings 30,127,177 shares OPKO common shares directly owned by Frost Nevada Investments Trust

Frost Nevada percentage 4.0% Share of OPKO’s outstanding common stock held by Frost Nevada

Stock options exercisable 2,425,000 shares OPKO options held by Frost, exercisable within 60 days

Key Terms

beneficially owns, restricted stock units, stock options, sole voting and dispositive power, +2 more

6 terms

beneficially owns financial

"Gamma Trust directly beneficially owns 216,706,448 shares of Common Stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

restricted stock units financial

"500,000 restricted stock units of which 250,000 units will vest within 60 days"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"stock options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

sole voting and dispositive power financial

"he has sole voting and dispositive power over each"

Schedule 13D regulatory

"This Amendment No. 28 amends and supplements the statement on Schedule 13D filed on February 15, 2007"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

outstanding shares financial

"based upon 746,328,225 shares of Common Stock outstanding as of June 29, 2026"

Outstanding shares are the total number of a company's stock units that are owned by all external investors and insiders, excluding any shares the company holds itself. They matter to investors because they determine each shareholder’s slice of ownership, how company value is divided per share (affecting price and earnings-per-share calculations), and the weight of voting power—like how slicing a pizza into more or fewer pieces changes the size of each person’s share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 07/01/2026 - 04:05 PM Accepted by SEC EDGAR 07/01/2026 - 04:04 PM

FAQ

How much of OPKO Health (OPK) stock does Phillip Frost currently beneficially own?

Phillip Frost beneficially owns 255,429,406 OPKO Health shares, representing about 34.1% of the company’s outstanding common stock. This total includes his personal holdings, shares in trusts he controls, options exercisable within 60 days, and certain restricted stock units scheduled to vest.

What percentage of OPKO Health (OPK) is held by Frost Gamma Investments Trust?

Frost Gamma Investments Trust directly beneficially owns 216,706,448 OPKO Health common shares, or approximately 29.0% of shares outstanding. Phillip Frost serves as sole trustee of Gamma Trust and holds sole voting and dispositive power over these shares, giving him significant influence over this large block.

What stake in OPKO Health (OPK) is reported by Frost Nevada Investments Trust?

Frost Nevada Investments Trust directly beneficially owns 30,127,177 OPKO Health common shares, representing about 4.0% of the company. Phillip Frost is the sole trustee of Frost Nevada and has sole voting and dispositive power over these shares, adding to his aggregate ownership position.

How many OPKO Health (OPK) shares are outstanding in this Schedule 13D/A amendment?

The filing states that OPKO Health has 746,328,225 shares of common stock outstanding as of June 29, 2026. This figure, communicated by the issuer, is used to calculate the ownership percentages reported for Phillip Frost, Frost Gamma Investments Trust, and Frost Nevada Investments Trust.

What OPKO Health (OPK) derivative and restricted stock interests does Phillip Frost report?

Phillip Frost reports stock options to acquire 2,425,000 OPKO Health shares exercisable within 60 days and 500,000 restricted stock units, of which 250,000 will vest within 60 days. Additional 250,000 restricted stock units are excluded because they will not begin vesting until July 2027.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 28)

OPKO HEALTH, INC.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

68375N103

(CUSIP Number)

Camielle Green
4400 Biscayne Blvd.,
Miami, FL, 33137
3055754100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, par value $0.01 per share

(b)

Name of Issuer:

OPKO HEALTH, INC.

(c)

Address of Issuer's Principal Executive Offices:

4400 BISCAYNE BLVD., MIAMI, FLORIDA , 33137.

Item 1 Comment:

This Amendment No. 28 (the "Amendment") amends and supplements the statement on Schedule 13D filed on February 15, 2007, as amended by Amendment No. 1 to the Schedule 13D filed on April 6, 2007, as amended by Amendment No. 2 to the Schedule 13D filed on August 2, 2007, as amended by Amendment No. 3 to the Schedule 13D filed on February 14, 2008, as amended by Amendment No. 4 to Schedule 13D filed on August 21, 2008, as amended by Amendment No. 5 to the Schedule 13D filed on February 26, 2009, as amended by Amendment No. 6 to the Schedule 13D filed on March 19, 2009, as amended by Amendment No. 7 to the Schedule 13D filed on October 1, 2009, as amended by Amendment No. 8 to the Schedule 13D filed on March 28, 2011, as amended by Amendment No. 9 to the Schedule 13D filed on October 24, 2011, as amended by Amendment No. 10 to the Schedule 13D filed on October 11, 2012, as amended by Amendment No. 11 to the Schedule 13D filed on March 21, 2013, as amended by Amendment No. 12 to the Schedule 13D filed on September 16, 2013, as amended by Amendment No. 13 to the Schedule 13D filed on February 17, 2015, as amended by Amendment No. 14 to the Schedule 13D filed on December 18, 2015, as amended by Amendment No. 15 to Schedule 13D filed on September 20, 2017, as amended by Amendment No. 16 to Schedule 13D filed on November 20, 2018, as amended by Amendment No. 17 to Schedule 13D filed on March 20, 2019, as amended by Amendment No. 18 to Schedule 13D filed on March 22, 2019, as amended by Amendment No. 19 to Schedule 13D filed on November 1, 2019, as amended by Amendment No. 20 to Schedule 13D filed on August 19, 2022, as amended by Amendment No. 21 to Schedule 13D filed on February 21, 2023, as amended by Amendment No. 22 to Schedule 13D filed on January 22, 2024, as amended by Amendment No. 23 to schedule 13D filed on January 24, 2024, as amended by Amendment No. 24 to schedule 13D filed on August 29, 2024, as amended by Amendment No. 25 to schedule 13D filed on November 15, 2024, as amended by Amended No. 26 to schedule 13D filed on April 3, 2025, as amended by Amendment No. 27 to schedule 13D filed on October 1, 2025 (collectively, the "Original Schedule 13D"), by The Frost Group, LLC (the "Frost Group"), a previously reporting entity, Frost Gamma Investments Trust ("Gamma Trust"), Frost Nevada Investments Trust ("Frost Nevada"), and Phillip Frost, M.D. ("Dr. Frost"). This Amendment is filed pursuant to the Joint Filing Agreement as executed by the reporting persons listed on the cover pages to this Amendment. The Joint Filing Agreement, filed as Exhibit 1 to Amendment No. 15 to the Schedule 13D filed on September 20, 2017, is hereby incorporated by this reference. This Amendment is filed with respect to the common stock, par value $0.01 per share ("Common Stock"), of OPKO Health, Inc., a Delaware corporation (the "Issuer"). This Amendment is being filed solely as a result of a change in the Issuer's number of outstanding shares of Common Stock.

Item 5.

Interest in Securities of the Issuer

(a)

Gamma Trust directly beneficially owns 216,706,448 shares of Common Stock, which constitute approximately 29.0% of the Issuer's outstanding shares of Common Stock, based upon 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person. Frost Nevada directly beneficially owns 30,127,177 shares of Common Stock, which constitute approximately 4.0% of the Issuer's outstanding shares of Common Stock, based upon 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person. Dr. Frost individually owns (i) 3,068,951 shares of Common Stock, (ii) stock options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and (iii) 500,000 restricted stock units of which 250,000 units will vest within 60 days of the date hereof, and he has sole voting and dispositive power over each. The Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. The 255,429,406 shares of Common Stock beneficially owned by Dr. Frost constitute approximately 34.1% of the Issuer's outstanding shares of Common Stock, based upon (i) 746,328,225 shares of Common Stock outstanding as of June 29, 2026 as communicated by the Issuer to the Reporting Person; (ii) options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof; and (iii) 250,000 restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock that will vest within 60 days of the date hereof. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock, which will not begin to vest until July, 2027.

(b)

Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 216,706,448 shares of Common Stock held by Gamma Trust. Dr. Frost is the sole trustee of Frost Nevada and holds sole voting and dispositive power with respect to 30,127,177 shares of Common Stock owned by Frost Nevada. The Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, owns 2,851,830 shares of Common Stock. Dr. Frost has shared voting and dispositive power with respect to 2,851,830 shares of Common Stock owned by the Phillip and Patricia Frost Philanthropic Foundation, Inc. Dr. Frost individually owns and has sole voting and dispositive power over each of (i) 3,068,951 shares of Common Stock, (ii) stock options to acquire 2,425,000 shares of Common Stock, which are exercisable within 60 days of the date hereof, and (iii) 250,000 restricted stock units that will vest within 60 days of the date hereof. Dr. Frost's ownership position excludes restricted stock units that give him a contingent right to receive up to 250,000 shares of Common Stock, which will not begin to vest until July, 2027.

(c)

In the last 60 days prior to the filing of this Amendment No. 28, Gamma Trust, Frost Nevada and Dr. Frost have not effected any transactions in the shares of Common Stock.

(d)

Except as described herein, no other person is known by any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FROST PHILLIP MD ET AL

Signature:	/s/ Phillip Frost, M.D.
Name/Title:	Phillip Frost, M.D., Individually
Date:	07/01/2026

Frost Gamma Investments Trust

Signature:	/s/ Phillip Frost, M.D.
Name/Title:	Phillip Frost, M.D. / Sole Trustee
Date:	07/01/2026

Frost Nevada Investments Trust

Signature:	/s/ Phillip Frost, M.D.
Name/Title:	Phillip Frost, M.D. / Sole Trustee
Date:	07/01/2026

Source: View Original Filing on SEC EDGAR